Abstract. Auron-Misheil-Therapy (AMT) consisting of aqueous camomile extract supplemented with calcium, vitamins, the antihistamine chlorpheniramine and human insulin is under development as anti-cancer treatment. AMT was preclinically investigated in tumour cell lines and tumour xenografts to guide clinical phase I/II studies. AMT was tested against 56 human tumour cell lines, in a clonogenic assay in 98 patient-derived xenografts and in in vivo studies. AMT showed in vitro cytotoxic activity with highest susceptibility in cervical cancer, glioblastoma and colon cancers. In the clonogenic assay, anti-cancer activity of AMT was most active in cervical and uterine tumours, in colon cancer, glioblastoma, leukaemia, melanoma and pancreatic cancer. In vivo, AMT showed slight activity in tumour xenograft models of colon and mammary cancer. It also showed immune stimulatory effects by induction of IL-6-and TNF-· secretion in human PBMCs. The immune stimulatory potential of AMT, together with slight anti-tumour efficacy observed in the present study, indicates a role of AMT in tumour therapy.
Introduction
In the search for novel, effective anti-cancer treatments not only pure compounds, usually with known modes of action are investigated, but also natural products or more complex preparations, whose substantial anti-tumour activity may be demonstrated before the precise mechanism of action is fully understood. As an example for the latter ones, aqueous extracts of the European mistletoe (Viscum album L.) have been widely used for decades as alternative or complementary treatment and adjuvant cancer therapy particularly in Germany, Austria and Switzerland (1) (2) (3) (4) (5) .
Auron-Misheil-Therapy (AMT) is another representative of a more complex formulation. From compassionate use programs among end-stage cancer patients since 1989, preliminary data have provided evidence of benefits in terms of improved quality of life, sometimes together with body weight gain and reduction of pain. AMT is at present under development as an anti-cancer agent in phase II clinical trials.
Preclinical research with AMT revealed pronounced anticancer activity in a range of human tumour models, including bladder, brain, colon, lung, breast, melanoma, prostate and cervix, as well as in cells derived from haematological malignancies, including leukaemias and lymphomas. At the same time, the precise mode of action of AMT remains to be determined. The evidence thus far indicates that its action is predominantly cytotoxic (i.e. actively killing cells) rather than cytostatic (inhibiting mitosis), but the anti-tumour activity of AMT is likely to depend on more than one mechanism, because of the number of different constituents.
This study summarizes the preclinical research with AMT with focus on its anti-tumour and immune stimulatory properties.
Materials and methods
Test compounds. Auron-Misheil-Therapy (AMT) was provided as sterile, ready-to-use solution by Micro Carrier Systems, Neuss and was stored at 4˚C until use. The single components of AMT, aqueous camomile extract (derived from 1.8 g camomile blossom), Calcium Sandoz + Vitamin C nents were tested at their respective final concentrations as they appear in AMT (see Table I ). A dilution scheme to prepare AMT is given in Table I . AMT (100 ml) consisted of 36.146 ml aqueous camomile extract, 35 .95 ml Calcium Sandoz + Vitamin C ® , 0.25 ml Phenol, 16 .67 ml Becozyme ® , 8.38 ml Allerfin ® , 2.514 ml Actrapid HM ® . Therefore, the single components were diluted with Aqua injectabilia according to Table I and were tested in a dose range of 0.0001% v/v to 10.0% v/v. Final dilutions were prepared in cell culture medium.
For in vivo studies the sterile, ready-to-use solution of AMT was administered intramuscularly at doses of 0.12 and 0.06 ml/mouse daily for up to 22 days. The daily dose was split and applied at hour 0 and 6. Control mice received saline solution as vehicle (0.12 ml/mouse/day) intramuscularly, using the corresponding administration schedule.
5-Fluorouracil (5-FU medac ® , Medac, Hamburg), dacarbazine (Detimedac ® , Medac, Hamburg), paclitaxel (Taxol ® , Bristol-Myers Squibb, Munich), gemcitabine (Gemzar ® , Lilly, Giessen), cyclophosphamide (Endoxan ® , Baxter, Frankfurt) were obtained as clinical formulations from the pharmacy and tested at the maximum tolerated dose in an optimized schedule.
Monolayer assay cytotoxicity assay. A modified propidium iodide assay was used to determine the cytotoxic activity of AMT against human tumour cell lines. The test procedure has been described elsewhere (6) . Cell lines tested were derived from patient tumours engrafted as a subcutaneously growing tumour in NMRI nu/nu mice, or obtained from the American Type Culture Collection, Rockville, MD, USA, National Cancer Institute, Bethesda, MD, USA, or Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany. Briefly, human tumour cell lines were grown at 37˚C in a humidified atmosphere (95% air, 5% CO 2 ) in monolayer cultures in RPMI-1640 medium supplemented with 10% fetal calf serum and phenol red (PAA, Cölbe, Germany). Cells were trypsinized and maintained weekly. Cells were harvested from exponentially growing cultures by trypsination, counted and plated in 96-well flat-bottomed micro plates (140 μl cell suspension, 5x10 3 to 10x10 3 cells/well). After a 24 h recovery to allow cells to resume exponential growth, 10 μl of culture medium (6 control wells per plate) or medium containing the test drug were added to the wells. Each drug concentration was plated in triplicate. After 4 days of incubation, the culture medium was replaced by fresh medium containing 6 μg/ml of propidium iodide. Microplates were then kept at -18˚C for 24 h, to give a total cell kill. After thawing of the plates, fluorescence was measured using the Cytofluor 4000 microplate reader (Perseptive Biosystems) (excitation 530 nm, emission 620 nm).
Clonogenic assays with human tumour xenografts and haematopoietic stem cells. Effects of AMT on clonogenicity of tumour cells were investigated in a clonogenic assay. Tumour xenografts were derived from patient tumours engrafted as a subcutaneously growing tumour in NMRI nu/nu mice obtained from Oncotest's breeding facility (7, 8) . Details of the test procedure have been described earlier (9) . Briefly, solid human tumour xenografts were removed from mice under sterile conditions, mechanically disaggregated and subsequently incubated with an enzyme cocktail consisting of collagenase type IV (41 U/ml), DNase I (125 U/ml), hyaluronidase type III (100 U/ml) and dispase II (1.0 U/ml) in RPMI-1640 medium at 37˚C for 45 min. Cells were passed through sieves of 200 and 50 μm mesh size and washed twice with sterile PBS-buffer. The percentage of viable cells was determined in a Neubauer-hemocytometer using trypan blue exclusion. The bottom layer consisted of 0.2 ml/well Iscove's Modified Dulbecco's Medium (Life Technologies), supplemented with 20% (v/v) fetal calf serum (Sigma), 0.01% (w/v) gentamicin (Life Technologies) and 0.75% (w/v) agar (BD Biosciences). Cells 1.5x10 4 to 4x10 4 were added to 0.2 ml of the same culture medium supplemented with 0.4% (w/v) agar and plated in 24-multiwell dishes onto the bottom layer. The test compounds were applied by continuous exposure (drug overlay) in 0.2 ml of culture medium. Every dish included 6 untreated control wells and drug-treated groups in triplicate at 6 concentrations. Cultures were incubated at 37˚C and 7.5% CO 2 in a humidified atmosphere for 7-20 days and monitored closely for colony growth using an inverted microscope. Within this period, in vitro tumour growth led to the formation of colonies with a diameter of >50 μm. At the time of maximum colony formation, counts were performed with an automatic image analysis system (OMNICON 3600, Biosys GmbH). Twenty-four hours prior to evaluation, vital colonies were stained with a sterile aqueous solution of 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride (1 mg/ml, 100 μl/well).
For testing haematopoietic stem cells, samples of bone marrow (2 donors) or cord blood (1 donor) were diluted 2-to 3-fold with PBS containing 0.1% (w/v) BSA. Mononuclear Table I . Constitution of AMT for testing individual components. 
cells were enriched from the respective samples by Ficoll Paque ® density gradient centrifugation and washed twice with PBS containing 0.1% (w/v) BSA. The resulting cell suspension was stored in aliquots in a freezing medium consisting of 90% v/v fetal calf serum and 10% v/v DMSO at -80˚C. Aliquots were thawed for testing as appropriate. The colony forming test was performed using 24-well plates and MethoCult GF (Stem Cell Technologies) as culture medium. Twenty-five thousand cells/ml of the above-mentioned preparation were seeded in a final volume of 500 μl per well. Solutions of the test compounds were added directly to the medium. Every dish included 6 untreated control wells and drug-treated groups in triplicate at 5 concentrations. Three wells of the test plate were filled with 1 ml of sterile water to ensure that maximum humidity was attained during the subsequent incubation period. Cultures were incubated at 37˚C and 7.5% CO 2 in a humidified atmosphere for 12 days. Colony growth was evaluated using an inverted microscope (10) .
In vivo evaluation in nude mice carrying tumour xenografts. In vivo efficacy of AMT was determined in mice carrying human tumour xenografts, and murine tumours, respectively. All experiments were conducted according to the guidelines of the German Animal Health and Welfare Act (Tierschutzgesetz). Animal health was examined at the day before tumour implantation and before randomization to ensure that only animals of good health were selected to enter testing procedures. The test procedure has been described elsewhere (11) . Briefly, tumour fragments of human tumour xenografts were implanted into the flanks of immune-deficient mice of NMRI nu/nu genetic background (Oncotest breeding facility, Freiburg, Germany). Tumour fragments of murine tumours were implanted into the flanks of C57/black6 mice (Bomholtgard Breeding and Research Center, Ry, Denmark). The fragments were obtained from tumours in serial passage, established either from direct implantation of patient material, or from injection of tumour cell lines obtained from the American Type Culture Collection, Rockville, MD, USA, National Cancer Institute, Bethesda, MD, USA, or Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany. Tumour growth was assessed by serial calliper measurements of two perpendicular tumour diameters. Treatment was started when tumours were palpable and reached a median volume of ~100 mm 3 , depending on tumour type. Each treatment group consisted of 8-11 mice. Animals with appropriate tumour volumes were randomly distributed into treatment and control groups (day 0). Tumour diameters and body weights were recorded twice weekly. For the evaluation of treatment efficacy, tumour volumes were calculated for each time point according to the formula (length x width 2 )/2 by using specifically designed software and by plotting the median relative tumour volume against time. Relative tumour volumes were calculated for each single tumour by dividing the tumour volume on day X by the initial tumour volume on day 0 at the time of randomization. A median body weight loss of >20% without recovery was considered not evaluable for anti-tumour efficacy. The U-Test by Mann-Whitney-Wilcoxon was used for the statistical analysis of the data based on median relative tumour volume parameters.
Immune stimulation. Peripheral blood mononuclear cells (PBMC) were isolated from freshly drawn human blood treated with EDTA as an anti-coagulant. Cells were diluted with 3 volumes of CliniMACS PBS/EDTA buffer (Miltenyi, Bergisch Gladbach), carefully layered over FicollPaque (GE Healthcare) in a conical tube and centrifuged at 400 x g for 40 min at 20˚C in a swinging-bucket rotor without brake. The upper layer was aspirated, leaving the mononuclear cell layer undisturbed at the interphase. The interphase cells (lymphocytes, monocytes and thrombocytes) were carefully transferred into a new conical tube. This was filled with CliniMACS PBS/EDTA buffer and centrifuged at 300 x g for 10 min at 20˚C. The supernatant was completely removed. For removal of platelets the cell pellet was resuspended in 50 ml buffer and centrifuged at 200 x g for 10 min at 20˚C. The supernatant was completely removed and the last washing step was repeated. Cells were resuspended in AIMV-Medium (Life Technologies, Karlsruhe) and counted in a Neubauerhaemocytometer.
For the stimulation of PBMC 250,000 cells per well were seeded in a 96-well plate. PBMC of 5 different healthy donors were stimulated with AMT (0.3% v/v), or a stimulation cocktail containing PMA 10 ng/ml (Sigma, Deisenhofen), Ionomycin 1 μg/ml (Sigma) and LPS 1 μg/ml (Linaris, Wertheim-Bettingen), respectively. Cells were incubated at 37˚C and 5% CO 2 in a humidified atmosphere for 24 h.
The supernatants from the stimulated PBMC were taken immediately before use and tested for cytokines by a cytometric bead assay (CBA). The supernatant from PBMC stimulated with the cocktail containing PMA, Ionomycin and LPS was used as an internal positive control. Before the cytokines were measured, the internal positive control and the AMT supernatants were diluted with CBA assay diluent. The cytokines interleukin (IL)-2, IL-4, IL-6, IL-10, tumour necrosis factor · (TNF-·) and interferon Á (IFN-Á) were quantitatively measured with a Coulter Cytomics FC500 cytometer using the CBA (Becton-Dickinson, San Diego) according to the manufacturer's instructions. The results were analyzed with the Coulter Cytomics Bead Array Analysis program.
Results

Auron-Misheil-Therapy (AMT).
AMT is a mixture of approved pharmaceuticals in low therapeutic doses and consists of an aqueous extract of camomile supplemented with calcium, vitamins, the antihistamine chlorpheniramine, and human insulin (Table II) . AMT was developed as a supportive therapy for patients with malignancies.
In vitro efficacy tests. In order to investigate its anti-tumour efficacy, AMT was tested in a broad panel of 56 permanent human tumour cell lines reflecting 12 different tumour types in vitro using a proliferation inhibition assay. The cell line panel comprised commercial available cell lines, as well as cell lines established from solid tumour xenografts which were directly derived from patient material. The ready-to-use AMT solution was added at concentrations ranging from 0.001% v/v to 10% v/v to the cell cultures, and inhibition of proliferation was measured. AMT showed concentration-dependent and selective inhibition of tumour cell growth. The concentrations of AMT, where 50 or 70% of the cells were inhibited in proliferation, are given in Table III (Table III) . Tumour cell lines of pancreatic cancer (PAXF 1657L, BXPC3), and renal cancer (RXF 1781L, RXF 393NL, RXF 486L, RXF 944L, CAKI-1) were generally less sensitive (Table III) .
Inhibition of clonogenicity of tumour cells by AMT was evaluated in additional tumour models using a clonogenic assay. The anti-proliferative activity of AMT was evaluated in cell suspensions freshly prepared from 98 different human tumour xenografts of 19 tumour types which grew as solid tumours in serial passage on immune-deficient nude mice. In addition, AMT was tested in 3 preparations of haematopoietic stem cells as a model system for non-malignant tissue. AMT inhibited anchorage-independent growth and in vitro colony formation of tumour cells in semi-solid medium. IC 50 values in the clonogenic assay ranged from 0.02% v/v to 6.61% v/v (Table IV) (Table IV) . Less activity was seen in tumour types such as liver cancer, non-small cell lung cancer and ovarian cancer (Tables IV and V) .
The single components of AMT at their respective final concentrations were evaluated separately for anti-tumour activity in comparison to the total AMT preparation in the clonogenic assay. Table II shows the concentrations of the single components as they occur in AMT, when the product is manufactured according to the composition shown in Table I . Four human tumour models, responsive towards AMT, were selected according to the above-mentioned test results, namely LXFA 629 (adeno lung cancer), MAXF 401 (adenocarcinoma of the breast), MEXF 462 (amelanotic melanoma), PAXF 1657 (adenocarcinoma of the pancreas). Fig. 1 shows the results at each drug concentration. AMT showed clear antitumour activity in a concentration range between 0.1% v/v and 10.0% v/v, which is in accordance to the response described above. At 1.0% v/v colony formation was inhibited by >70% in 3/4 tumour models, and at 3.0 and 10.0% v/v, in all tumour models tested. Calcium Sandoz + Vitamin C was active at concentrations of 3.0% v/v (inhibition of 2/4 tumour models) and 10.0% v/v (4/4). The aqueous camomile extract was active in 3/4 tumour models at the highest test concentration of 10% v/v (Fig. 1) .
Slight inhibitory effects were obtained for Allerfin and Becozyme. Allerfin inhibited colony growth at the highest test concentration in the lung cancer model LXFA 629 and the mammary cancer model MAXF 401 with T/C = 30% in each case, but was inactive in the two other tumour models. Becozyme effected inhibition in colony growth at the highest test concentration in the melanoma model MEXF 462 with T/C = 38%, but was totally inactive in all other tumour models. No anti-tumour activity was seen in case of Actrapid HM (Fig. 1) . Overall, the activity of AMT was strikingly higher than that of any single component.
In vivo efficacy tests. AMT was tested in six human xenograft models which have been identified to be sensitive to AMT treatment in vitro (see above), as well as in three different models of murine tumours. Anti-tumour efficacy was measured as tumour volume inhibition and growth delay over time. Side effects were determined as lethality and body weight loss. AMT was administered intramuscularly at dose levels of 0.12 and 0.06 ml/mouse daily for up to 22 days. The daily dose was split and applied at hour 0 and 6. Standard anticancer drugs, administered at their maximum tolerated dose and optimal schedule, were used as positive controls. AMT was well tolerated in all experiments with median body weight increase in the range of 2-7%. AMT given at 0.06 ml/mouse/ day showed slight anti-tumour activity in the human mammary Table III . Cytotoxic activity of AMT against 56 human tumour cell lines tested in vitro in a monolayer proliferation assay. -----------------------------------------------------------------------------------------------------Figure 1 . Anti-tumour activity of AMT and single components thereof in vitro using a clonogenic assay. Table IV . Cytotoxic activity of AMT against 98 human tumour xenografts tested in vitro in a clonogenic assay.
-----------------------------------------------------------------------------------------------------Tumour type Tumour cell line IC 50 (% v/v) -----------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------Tumour type
Tumour xenograft IC 50 Mean IC 50 1. 0  ----------------------------------------------------------------------------------------------------- cancer model MAXF 401 (optimal T/C of 71%), as well as in the murine melanoma B-16 (optimal T/C of 63%), and given at 0.12 ml/mouse/day in the murine colon adenocarcinoma colon 38 (optimal T/C of 65%) (Table VI) . AMT revealed the greatest inhibitory effect in the human colon cancer model CXF 1753 with an optimal T/C of 67% at 0.06 ml/mouse on day 28 which was significant (p<0.05) (Table VI, Fig. 2 ). Anti-tumour efficacy was generally not strictly dosedependent. CXF 1753 responded to the positive control 5-fluorouracil which was given at 100 mg/kg/d i.p. on days 0, 7 and 14 with an optimal T/C value of 27% on day 28 (Fig. 2) .
(% v/v) -----------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------Tumour type Tumour xenograft IC 50 (% v/v) -----------------------------------------------------------------------------------------------------
The human melanoma MEXF 989, the lung adenocarcinoma LXFA 629, the pancreatic adenocarcinoma PAXF 1657, and the leukaemia CCRF-CEM (optimal T/C values ranging from 78 to 100%) and the murine Lewis lung adenocarcinoma (optimal T/C of 84%) were resistant to AMT treatment (Table VI) . The standard anti-cancer drugs used as positive controls, dacarbazine (MEXF 989), paclitaxel (LXFA 629), gemcitabine (PAXF 1657), cyclophosphamide (CCRF-CEM), showing significant inhibition of tumour growth in each case (Table VI) .
Immune stimulatory effects. The immune stimulating of AMT was investigated on PBMCs of five different healthy donors. AMT was tested at a subtoxic concentration of 0.3% v/v. The secretion of IL-2, IL-4, IL-6, IL-10, TNF-· and IFN-Á was quantitatively measured by flow cytometry. AMT clearly Table V . Tumour type selectivity of AMT in human tumour xenografts tested in vitro in a clonogenic assay. - Table VI . Inhibition of tumour growth by AMT tested in vivo in tumour-bearing mice. - ---------------------------------------------------------------------------------------------------- induced the secretion of the cytokines IL-6 and TNF-· in 4/5 donors. Levels of detected IL-6 were in the range between 3.4 and 20.0 ng/ml at 0.3% v/v AMT, compared to a IL-6 secretion range of 0.067 to 0.29 ng/ml in case of the positive control (a stimulation cocktail of LPS, PMA and ionomycin) in these donor preparations (Fig. 3) . TNF-· levels in successfully stimulated blood samples were between 0.04 and 0.65 ng/ ml in case of AMT (0.3% v/v) and between 1.1 and 2.4 ng/ml in case of the positive control (Fig. 3) . Background levels of IL-6 and TNF-· in unstimulated PBMCs were <0.007 ng/ml (Fig. 3) . In addition, a moderate elevation of IL-2, IL-4 and IL-10 could be detected in individual blood samples, but this effect was not consistent among all samples investigated (Fig. 3) .
------------------------------------------------
----------------------------------------------------------------------------------------------------- AMT Positive controls ----------------------------------------------------------------- Tumour type Tumour model Dose (ml/mouse/day) a Optimum T/C (%) Compound b Optimum T/C (%) ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Discussion
In contrast to pure compounds with defined chemical structure, the basis of AMT is an aqueous extract of camomile, supplemented with calcium, several vitamins, the antihistamine chlorpheniramine, and human insulin. Despite the difficulty of allocating an active principle in such a complex compound mixture with the therapeutic use of such preparations, the therapeutic use of phytotherapeutic medicines is generally accepted, e.g. the use of St. John's Wort as antidepressant for treatment of mild to moderately severe depression (12) (13) (14) , the sleep enhancing effect of valerian (15) , or the use of aqueous extracts of the European mistletoe (Viscum album L.) as alternative treatment and adjuvant cancer therapy particularly in Germany, Austria and Switzerland (1) (2) (3) (4) (5) . The objective of the present study was to investigate anti-tumour efficacy of AMT in vitro and in vivo in tumour cell lines and tumour xenografts in order to understand the therapeutic potential of the preparation.
The in vitro anti-proliferative activity of AMT was evaluated in panels of permanent human tumour cell lines and human tumour xenografts growing as colonies in soft agar. AMT showed concentration-dependent and selective inhibition of proliferation in several human tumour cell lines of cervical cancer, colon cancer, glioblastoma, ovarian cancer, leukaemia, and lymphoma. These findings provide evidence for the antineoplastic potency of AMT. Using a clonogenic assay, AMT was further characterized for its ability to inhibit anchorageindependent growth and in vitro colony formation of tumour cells in semi-solid medium. The test panel of 98 tumours, representing 19 different tumour types, aimed to reflect the heterogeneity of human tumours seen in clinical studies. The tumour cell preparations for the clonogenic assay were prepared directly from human tumour xenografts growing in nude mice. Based on the heterogeneity of growing solid tumour, these preparations comprised tumour stem cells to a certain extent which are discussed to be responsible for the metastatic and infiltrative potential of a tumour (16) (17) (18) (19) (20) . Hence, the clonogenic assay reflects better the in vivo situation than in vitro assays using permanent tumour cell lines and has been found to be a predictive test for further in vivo evaluation of anti-cancer drugs (9, (21) (22) (23) (24) . AMT inhibited colony formation of tumour cells in semi-solid medium, and based on the distribution of IC 50 values, tumour types such as cervical cancer, colon cancer, glioblastoma, leukaemia, melanoma, and pancreatic cancer were identified to be most sensitive towards AMT. Based on IC 50 values, these sensitive tumour models were on average ~4-fold more sensitive than the mean IC 50 of all models tested, indicating a tumour selective way of growth inhibition. Moreover, these sensitive tumour models were slightly more sensitive than haematopoietic stem cells as representative model system for non-malignant tissue. Thus, inhibition of colony formation of haematopoietic stem cells was in an acceptable range.
In order to allocate the anti-tumour activity of AMT to an active constituent, the single components of AMT were tested in comparison to the whole formulation in four different tumour models. There was clear anti-tumour activity of part, but not all of the components. Calcium Sandoz + Vitamin C, the aqueous camomile extract and phenol showed most inhibition of colony formation. However, the activity of AMT was strikingly higher than that of any single component. Thus, the anti-tumour activity of AMT benefits from the combination of all single components. Besides the aqueous camomile extract, calciumglubionate is present in the mixture at the highest concentration of all single compounds, and activity of Calcium Sandoz + Vitamin C could be demonstrated in the present study. Calcium as a ubiquitous second messenger regulates many cellular functions, including cell growth, differentiation and apoptosis (25) (26) (27) . In addition, it was shown by several groups, that calcium can slow down cancer cell division, and administration of calcium offers an approach to the primary prevention of intestinal neoplasia and/or therapy of colorectal cancer metastases (28) (29) (30) . In this manner, calcium probably contributes to the anti-tumour activity of AMT. But clearly, progress towards the clinical use of AMT will require detailed investigation into the precise role of each of its constituents.
In subsequent in vivo studies in tumour xenografts, established in immune-deficient nude mice, administrations of AMT at doses of 0.12 or 0.06 ml/mouse/day, respectively, were well tolerated. The dose level of 0.12 ml/mouse/day corresponds to 3.6 ml/kg/day, equal to 6.48 ml/m 2 body surface (31). This dose is in agreement with the dose used in the clinical set-up with cancer patients who are treated with 5 ml AMT twice daily, equal to 10 ml/patient/day, or 5.56 ml/ m 2 body surface. Slight anti-tumour activity was observed in a well differentiated, papillary breast adenocarcinoma, derived from a lung metastasis of a 51-year old female patient (MAXF 401), as well as in the murine melanoma B-16, and the murine colon adenocarcinoma colon 38. However, tumour growth inhibition was not significant, and not as pronounced as the respective positive control paclitaxel in case of MAXF 401. Significant inhibition of tumour growth was observed in a colon adenocarcinoma xenograft model, derived from an abdominal wall metastasis of a 61-year old male patient (CXF 1753), but tumour growth inhibition was not as pronounced as the positive control 5-fluorouracil in this model.
The immune stimulating potency of AMT was shown in experiments with isolated PBMCs, where AMT induced the secretion of IL-6 and TNF-·. IL-6, also known as interferon-ß 2 (IFN-ß 2 ), T-cell replacing factor (TRF)-like factor, B cell differentiation factor (BCDF), B-cell stimulatory factor-2 (BSF-2), hybridoma-plasmacytoma growth factor (HPGF), hepatocyte stimulating factor (HSF), or monocytegranulocyte inducer type-2 (MGI-2), is a multifunctional cytokine which is produced by a variety of cells including T-and B cells and monocytes. IL-6 regulates immune responses, acute phase reactions and haematopoiesis (32) (33) (34) (35) , and is involved in T cell activation, growth and differentiation (35, 36) . It is known to induce serine esterase and perforin which are required for target cell lysis in the granules of cytotoxic T cells (37, 38) which are described to play an important role in the direct recognition and killing of immunogenic tumour cells. IL-6 has shown activity against cancer cells (39, 40) , but was also found to be a growth factor for myeloma cells (41, 42) . TNF-· is produced by immune cells including T cells, B cells, NK cells and monocytes. TNF-· was originally characterized as an anti-tumour protein inducing necrosis of MethA sarcomas in vivo (43) . TNF-· has been extensively studied and considered as an anti-tumour drug. It was applied intra-tumourally in cancer patients and some efficacy could be observed (44, 45) . However, the use of TNF-· as a single systemic agent in high doses has shown toxic side effects (46, 47) . Mechanisms of action, that have been suggested for the anti-tumour effect of TNF-·, include direct cytotoxicity against tumour cells, activation of immune anti-tumour response and selective damage of tumour blood vessels (48) . In acute phase reactions which occur e.g. during early phases of an infection IL-6 and TNF-· have a wide spectrum of biological activities that help to coordinate the body's response. Some of the effects e.g. increased activation of B-and T lymphocytes and phagocytosis, are also important in anti-tumoural immune responses. The secretion of IL-6 and TNF-· was induced during incubation of PBMCs with AMT. It has been described that aqueous extracts of the European mistletoe (Viscum album L.) also stimulate immunological relevant immune effector cells like macrophages, natural killer cells, as well as B-and T lymphocytes with subsequent release of cytokines, such as IL-1, IL-6, IL-10, TNF-· and granulocyte macrophage colony stimulating factor (49) (50) (51) (52) (53) . These effects contributed to the established use of such extracts for stimulation of the immune system in patients suffering from malignant tumours (54) .
At present, AMT is under the development as an anticancer agent. From compassionate use programs among end-stage cancer patients in the Middle East since 1989, preliminary data have provided evidence of benefits in terms of improved quality of life, sometimes together with body weight gain and reduction of pain. During clinical studies, it would now be of interest also to monitor cytokine levels in serum of patients before and after treatment. The immune stimulatory potential of AMT together with the slight antitumour efficacy observed in the present study indicate a role of AMT in tumour therapy.
